Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Duration of Antibiotic Treatment for Early VAP (DATE) Trial (DATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01994980
Recruitment Status : Suspended (Pending IRB continuing review approval.)
First Posted : November 26, 2013
Last Update Posted : April 3, 2019
Sponsor:
Information provided by (Responsible Party):
Fredric Pieracci, Denver Health and Hospital Authority

Brief Summary:
Hypothesis: 4 days of antibiotic therapy, as compared to 8 days, is equally effective and results in decreased antibiotic exposure among surgical ICU patients with early VAP.

Condition or disease Intervention/treatment Phase
Early Ventilator Associated Pneumonia Drug: Default 4 days antibiotic therapy Not Applicable

Detailed Description:

The prevalence of multi-drug resistant (MDR) pathogens in intensive care units (ICUs) worldwide has reached epidemic proportions. In some cases, the choice of potential therapy is limited or even non-existent. Antibiotic prescription, through selection pressure, represents the main mechanism by which resistance emerges. Limitations in the development of new antibiotics underscores the importance of adherence to the principles of antibiotic stewardship.

Ventilator associated pneumonia (VAP) is the most common serious infection in mechanically ventilated, critically ill patients. Approximately one half of antibiotic prescription in the ICU is related to VAP, including prophylactic, empiric, and definitive therapy. The development of evidence-based algorithms for the rational use of antibiotics in the management of patients with both suspected and confirmed VAP is pivotal to decreasing the emergence of MDR pathogens.

Shortening the duration of antimicrobial therapy for VAP represents one strategy to curtail the emergence of MDR pathogens. Although current guidelines recommend a treatment course of 8-14 days, both clinical and microbiologic resolution (MR) of infection typically occur much sooner [10, 11]. In one study of ICU patients ventilated for > 5 days who developed VAP, 8 days of antimicrobial therapy was equally as effective as 14 days, provided VAP was not caused by a non-lactose fermenting gram negative bacillus. Favorable results following shorter courses of therapy for VAP have been observed, albeit in small, uncontrolled series.

One subset of patients for whom a decreased duration of antimicrobial therapy may be particularly effective is those who develop VAP ≤ 5 days after intubation (early VAP). Early VAP comprises approximately one half of cases of pneumonia diagnosed in the ICU. Furthermore, as compared to patients who develop late VAP, patients who develop early VAP are more likely to be infected with community-acquired pathogens sensitive to narrow spectrum antibiotics. Finally, nearly all cases of early VAP caused by sensitive pathogens demonstrate MR after relatively short (3-5 days) courses of therapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Clinical Trial of 4 vs. 8 Days of Definitive Antibiotic Therapy for Early Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit
Study Start Date : December 2013
Estimated Primary Completion Date : February 13, 2020
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Default 4 days antibiotic therapy
Default 4 days antibiotic therapy
Drug: Default 4 days antibiotic therapy
The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
Other Name: Antibiotic for 4 days

No Intervention: Default 8 days antibiotic therapy
Default 8 days antibiotic therapy



Primary Outcome Measures :
  1. Clinical Response [ Time Frame: Daily for 28 days ]
    CPIS score


Secondary Outcome Measures :
  1. Biomarker response [ Time Frame: Daily for either 4 or 8 days, dependent upon treatment arm ]
    Procalcitonin

  2. Microbiologic response [ Time Frame: 1 Day after last day of treatment ]
    BAP culture <10^3 cfu/mL

  3. Infection with MDR pathogen [ Time Frame: 28 days ]
    The patient has growth of a multidrug resistant pathogen on culture

  4. Recurrence [ Time Frame: 28 days ]
    The patient has another occurrence of VAP after treatment

  5. Ventilator free days [ Time Frame: 28 days ]
    The number of day the patient does need mechanical ventilation

  6. Mortality [ Time Frame: 28 days ]
    The patient has died



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Surgical patient
  2. VAP, defined as clinical suspicion plus a bronchoalveolar lavage (BAL) culture showing ≥105 cfu/mL of at least one pathogen. The quantitative microbiology threshold will be lowered to ≥104 cfu/mL if the patient was being treated with antibiotics to which the pathogen is sensitive at the time of the BAL. Clinical suspicion of VAP is defined as at least one point for ≥ 2 variables in the Clinical Pulmonary Infection Score (CPIS, described below).
  3. Ventilated ≤ 5 days at the time that the BAL was obtained.
  4. Hospital LOS ≤ 5 days at the time that the BAL was obtained.

Exclusion Criteria:

  1. Age < 18 years.
  2. Prior episode of VAP for the index admission (the patient may have had prior BALs sent for culture, but these cannot have met the above mentioned diagnostic criteria for VAP).
  3. VAP caused by a MDR pathogen: Early VAP is rarely caused by a MDR pathogen; in a recent analysis of our surgical ICU, 94% of cases of early VAP were caused by a highly sensitive pathogen (MSSA 39%, H flu 35%, S. pneumo 16%, E. coli 9%) (Pieracci in press). Patients with early VAP caused by the following MDR pathogens will be excluded: Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-intermediate Staphylococcus aureus (VISA), pseudomonas aeruginosa, Vancomycin-resistant enterococcus (VRE), Acinetobacter baumannii, Stenotrophomonas maltophilia, and extended-spectrum beta lactamase producing gram negative bacilli.
  4. Antibiotic therapy for ≥ 5 of the last 10 days preceding the BAL.
  5. Septic shock, defined as evidence of tissue hypoperfusion after adequate volume expansion, due to infection, and requiring ≥ 1 vasopressor.
  6. Current or recent (within 30 days) use of immunosuppressive medications.
  7. Length of stay ≥ 48 hours in a transferring facility.
  8. Inpatient hospitalization within 30 days of admission.
  9. Pregnancy or lactation.
  10. Legal arrest or incarceration.
  11. Moribund state in which death is imminent.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01994980


Locations
Layout table for location information
United States, Colorado
Denver Health Medical Center
Denver, Colorado, United States, 80204
Sponsors and Collaborators
Denver Health and Hospital Authority
Investigators
Layout table for investigator information
Principal Investigator: Fredric Pieracci, MD MPH Denver Health and Hospital

Layout table for additonal information
Responsible Party: Fredric Pieracci, Assistant Professor of Surgery, Denver Health and Hospital Authority
ClinicalTrials.gov Identifier: NCT01994980     History of Changes
Other Study ID Numbers: 13-0205
First Posted: November 26, 2013    Key Record Dates
Last Update Posted: April 3, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection
Infection
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents